Detectable Vesicular Stomatitis Virus (VSV)–Specific Humoral and Cellular Immune Responses Following VSV–Ebola Virus Vaccination in Humans-Reference-Cited by-同舟云学术

Detectable Vesicular Stomatitis Virus (VSV)–Specific Humoral and Cellular Immune Responses Following VSV–Ebola Virus Vaccination in Humans

Published:2018-11-17 Issue:4 Volume:219 Page:556-561
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Poetsch Joseph H¹²³,Dahlke Christine¹²³,Zinser Madeleine E¹²³,Kasonta Rahel¹²,Lunemann Sebastian⁴,Rechtien Anne¹²³⁴,Ly My L¹²³,Stubbe Hans C¹²⁵,Krähling Verena⁶⁷,Biedenkopf Nadine⁶⁷,Eickmann Markus⁶⁷,Fehling Sarah K⁶⁷,Olearo Flaminia¹,Strecker Thomas⁶⁷,Sharma Piyush⁸,Lang Karl S⁸,Lohse Ansgar W¹²,Schmiedel Stefan¹³,Becker Stephan⁶⁷^ORCID,Siegrist Claire-Anne,Huttner Angela,Addo Marylyn M,Becker Stephan,Krähling Verena,Bejon Phillip,Njuguna Patricia,Ndungu Francis,Kremsner Peter G,Brosnahan Jessica S,Agnandji Selidji Todagbe,Krishna Sanjeev,Kieny Marie Paule,Modjarrad Kayvon,Moorthy Vasee,Fast Patricia,Savarese Barbara,Lapujade Olivier,Addo Marylyn M¹²³,

Affiliation:

1. First Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg

2. German Center for Infection Research, partner site Hamburg-Lübeck-Borstel-Riems

3. Division of Infectious Diseases, University Medical Center Hamburg-Eppendorf

4. Leibniz Institute for Experimental Virology, Heinrich Pette Institute, Hamburg

5. Division of Infectious Diseases, Department of Medicine II, Ludwig Maximilian University, Munich

6. Institute for Virology, Philipps University Marburg

7. German Center for Infection Research, partner site Gießen-Marburg-Langen

8. Institute of Immunology, University Duisburg-Essen, Essen, Germany

Abstract

This study investigates preexisting and vaccine-induced vector immunity in 30 participants of a Phase-1 VSV-EBOV Ebola vaccine trial. No preexisting immunity was detected, however humoral and cell-mediated immunity against internal VSV proteins was observed in up to 36% of vaccines.

Funder

Wellcome Trust

German Center for Infection Research

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/article-pdf/219/4/556/27636094/jiy565.pdf

Reference15 articles.

1. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe;Agnandji;N Engl J Med,2016

2. Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic;Coller;Vaccine,2017